Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Biologics Bill’s Key Battleground May Be Senate Health Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.
Advertisement

Related Content

Generic Biologic Bill Needs Clinical Data Requirements, Sen. Hatch Says
Generic Biologic Bill Needs Clinical Data Requirements, Sen. Hatch Says
Indian Companies Ramping Up For Follow-On Biologics
Indian Companies Ramping Up For Follow-On Biologics
Indian Companies Ramping Up For Follow-On Biologics
BIO Charges Express Scripts, PCMA With Over Estimating Follow-On Biologic Savings
BIO Charges Express Scripts, PCMA With Over Estimating Follow-On Biologic Savings
Follow-On Biologics Would Save $71 Billion Over 10 Years, Express Scripts Estimates
Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability
Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability

Topics

Advertisement
UsernamePublicRestriction

Register

PS065630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel